ASH 2022 Primary Results of STIMULUS-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition With Sabatolimab Added to HMAs in Adult Patients With Higher-Risk MDS

ASH 2022 Primary Results of STIMULUS-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition With Sabatolimab Added to HMAs in Adult Patients With Higher-Risk MDS

Read the full article here

Related Articles